Pastuszak M, Cubala W, Jakuszkowiak-Wojten K, Kwasny A, Swieczkowski D, Galuszko-Wegielnik M
Neuropsychopharmacol Rep. 2025; 45(1):e12519.
PMID: 39783764
PMC: 11713126.
DOI: 10.1002/npr2.12519.
Wu Y, Cai J, Liu H, Li C, Tang Q, Zhang Y
Pharmaceuticals (Basel). 2025; 17(12.
PMID: 39770479
PMC: 11678425.
DOI: 10.3390/ph17121637.
Qian X, Li Q, Zhu H, Chen Y, Lin G, Zhang H
Cell Rep Med. 2024; 5(11):101798.
PMID: 39471819
PMC: 11604549.
DOI: 10.1016/j.xcrm.2024.101798.
Kwasny A, Cubala W, Wlodarczyk A, Pastuszak K
Pharmacol Rep. 2024; 76(6):1325-1332.
PMID: 39207673
PMC: 11582297.
DOI: 10.1007/s43440-024-00641-1.
Pastuszak M, Cubala W, Kwasny A, Mechlinska A
J Pers Med. 2024; 14(8).
PMID: 39202019
PMC: 11355381.
DOI: 10.3390/jpm14080828.
Overcoming treatment-resistant depression with machine-learning based tools: a study protocol combining EEG and clinical data to personalize glutamatergic and brain stimulation interventions (SelecTool Project).
Pettorruso M, Di Lorenzo G, Benatti B, dAndrea G, Cavallotto C, Carullo R
Front Psychiatry. 2024; 15:1436006.
PMID: 39086731
PMC: 11288917.
DOI: 10.3389/fpsyt.2024.1436006.
Major challenges in youth psychopathology: treatment-resistant depression. A narrative review.
Menculini G, Cinesi G, Scopetta F, Cardelli M, Caramanico G, Balducci P
Front Psychiatry. 2024; 15:1417977.
PMID: 39056019
PMC: 11269237.
DOI: 10.3389/fpsyt.2024.1417977.
Altered blood parameters in "major depression" patients receiving repetitive transcranial magnetic stimulation (rTMS) therapy: a randomized case-control study.
Ozkan B, Bozali K, Boylu M, Velioglu H, Aktas S, Kirpinar I
Transl Psychiatry. 2024; 14(1):264.
PMID: 38918365
PMC: 11199570.
DOI: 10.1038/s41398-024-02942-8.
Development of heterocyclic-based frameworks as potential scaffold of 5-HT1A receptor agonist and future perspectives: A review.
Yuan W, Ma Y, Zhang H
Medicine (Baltimore). 2024; 103(24):e38496.
PMID: 38875413
PMC: 11175882.
DOI: 10.1097/MD.0000000000038496.
Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression.
Kwasny A, Cubala W, Wlodarczyk A
Front Psychiatry. 2024; 15:1334293.
PMID: 38439794
PMC: 10909946.
DOI: 10.3389/fpsyt.2024.1334293.
Overcoming treatment gaps in the management of depression with non-pharmacological adjunctive strategies.
Purebl G, Schnitzspahn K, Zsak E
Front Psychiatry. 2023; 14:1268194.
PMID: 38090695
PMC: 10715434.
DOI: 10.3389/fpsyt.2023.1268194.
Engeletin alleviates depression-like phenotype by increasing synaptic plasticity via the BDNF-TrkB-mTORC1 signalling pathway.
Xu Y, Zhang J, Yu L, Zhang W, Zhang Y, Shi Y
J Cell Mol Med. 2023; 27(23):3928-3938.
PMID: 37799103
PMC: 10718134.
DOI: 10.1111/jcmm.17975.
DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs.
Del Casale A, Simmaco M, Modesti M, Zocchi C, Arena J, Bilotta I
Biomedicines. 2023; 11(7).
PMID: 37509727
PMC: 10377184.
DOI: 10.3390/biomedicines11072088.
Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder.
Galuszko-Wgielnik M, Jakuszkowiak-Wojten K, Wiglusz M, Cubala W, Pastuszak M
Front Neurosci. 2023; 17:1214972.
PMID: 37496742
PMC: 10366536.
DOI: 10.3389/fnins.2023.1214972.
Residual insomnia in major depressive disorder: a systematic review.
Kwasny A, Wlodarczyk A, Dywel A, Szarmach J, Strandberg O, Cubala W
Front Psychiatry. 2023; 14:1190415.
PMID: 37398584
PMC: 10312086.
DOI: 10.3389/fpsyt.2023.1190415.
Effect of Ketamine on Sleep in Treatment-Resistant Depression: A Systematic Review.
Kwasny A, Wlodarczyk A, Ogonowski D, Cubala W
Pharmaceuticals (Basel). 2023; 16(4).
PMID: 37111325
PMC: 10143949.
DOI: 10.3390/ph16040568.
The Role of Gasotransmitter-Dependent Signaling Mechanisms in Apoptotic Cell Death in Cardiovascular, Rheumatic, Kidney, and Neurodegenerative Diseases and Mental Disorders.
Rodkin S, Nwosu C, Sannikov A, Tyurin A, Chulkov V, Raevskaya M
Int J Mol Sci. 2023; 24(7).
PMID: 37046987
PMC: 10094524.
DOI: 10.3390/ijms24076014.
Inflammation, stress and depression: An exploration of ketamine's therapeutic profile.
Johnston J, Greenwald M, Henter I, Kraus C, Mkrtchian A, Clark N
Drug Discov Today. 2023; 28(4):103518.
PMID: 36758932
PMC: 10050119.
DOI: 10.1016/j.drudis.2023.103518.
Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.
Galuszko-Wegielnik M, Chmielewska Z, Jakuszkowiak-Wojten K, Wiglusz M, Cubala W
Brain Sci. 2023; 13(1).
PMID: 36672123
PMC: 9856721.
DOI: 10.3390/brainsci13010142.
The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.
Wilkowska A, Cubala W
Int J Mol Sci. 2022; 23(23).
PMID: 36498934
PMC: 9738502.
DOI: 10.3390/ijms232314605.